Nicoletta Cerana, president of Acto, expresses her satisfaction for how over the years research has made progress in the field of gynecological cancers. The latest news concerns the approval in Italy of dostarlimab, the monoclonal antibody effective against endometrial cancer.
#Cerana #Acto #Epochal #revolution #field #gynecological #cancers